In light of the previously identified mechanism, we conducted a clinical investigation to explore the association between the expression levels of METTL3 and G6PD, as determined by immunochemistry (IHC) assays, and the responses to OXA-based HAIC in HCC. The gene discussed is METTL3; the disease is hepatocellular carcinoma.